From Financial Modeling Prep: 2025-05-19 17:12:00

VolitionRx Limited, trading on the NYSE American as AMEX:VNRX, saw its CEO purchase 20,000 shares, signaling strong insider confidence. The company is known for its groundbreaking research in veterinary cancer screening, targeting a market of over 60 million cats in the U.S. Despite this success, financial challenges persist with high valuation metrics and liquidity concerns.



Read more at Financial Modeling Prep:: VolitionRx Limited’s Strategic Moves and Financial…